Kazia Therapeutics ( (KZIA) ) has shared an update.
Kazia Therapeutics released its Annual Report for the fiscal year ending June 30, 2024, highlighting significant progress in its drug development programs. The company has made strides with its lead asset, paxalisib, receiving Fast Track Designation from the FDA and showing promising clinical results in trials for brain metastases and other cancers. Additionally, Kazia’s strategic decision to delist from the ASX and focus on NASDAQ aims to enhance its capital-raising capabilities. The company also reported successful completion of a Phase 1 trial for EVT-801, targeting advanced solid tumors, with encouraging results particularly in ovarian cancer. These developments position Kazia to potentially improve patient outcomes and expand its market presence.
More about Kazia Therapeutics
Kazia Therapeutics is a biotechnology company focused on developing innovative cancer therapies. The company is advancing two primary drug candidates, paxalisib and EVT-801, through various clinical trials aimed at addressing unmet needs in cancer care.
YTD Price Performance: -43.74%
Average Trading Volume: 2,072,598
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $5.02M
Learn more about KZIA stock on TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com